Jiangsu Recbio Technology Co., Ltd. (HKG:2179)
Hong Kong · Delayed Price · Currency is HKD 3.800
-0.100 (-2.56%)
Oct 22, 2026, 9:31 AM HKT
Jiangsu Recbio Technology Revenue
Jiangsu Recbio Technology had revenue of 7.50M CNY in the half year ending June 30, 2026, a decrease of -57.46%. This brings the company's total for the last twelve months to 492.00K, down -76.67% year-over-year. In the year 2025, Jiangsu Recbio Technology had annual revenue of 12.73M. That makes Jiangsu Recbio Technology the 46,283rd largest company in the world by revenue and 2,604th in Hong Kong.
Revenue (ttm)
492.00K CNY
Revenue Growth
-76.67%
P/S Ratio
4,235.15
Revenue / Employee
1.06K CNY
Employees
466
Market Cap
2.34B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.73M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 30.38M | 25.05M | 470.46% |
| Dec 31, 2022 | 5.33M | -874.00K | -14.10% |
| Dec 31, 2021 | 6.20M | 4.74M | 325.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.20B |
| Frontage Holdings | 2.18B |
| AIM Vaccine | 1.16B |
| Mabpharm | 888.77M |
| Shandong Boan Biotechnology | 720.87M |
| Antengene Corporation | 652.54M |
| Medtide | 635.93M |
| BioDlink International Company | 582.45M |
Jiangsu Recbio Technology News
- 2 months ago - Jiangsu Recbio Technology Earnings release: H1 2026 - Filings
- 2 months ago - Jiangsu Recbio Technology Quarterly report: H1 2026 - Filings
- 7 months ago - Jiangsu Recbio Technology Earnings release: H2 2025 - Filings
- 7 months ago - Jiangsu Recbio Technology Annual report: H2 2025 - Filings